Femara, Seroquel, Razadyne ER Paragraph IV Certifications Filed
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification for Novartis' breast cancer agent Femara (letrozole) was filed March 2, according to FDA's May 2 updated list of filings